2-(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole

ID: ALA2313487

Chembl Id: CHEMBL2313487

PubChem CID: 71546668

Max Phase: Preclinical

Molecular Formula: C28H26N2O5S

Molecular Weight: 502.59

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cc(Cc2c(-c3ccn(S(=O)(=O)c4ccccc4)c3)[nH]c3ccccc23)cc(OC)c1OC

Standard InChI:  InChI=1S/C28H26N2O5S/c1-33-25-16-19(17-26(34-2)28(25)35-3)15-23-22-11-7-8-12-24(22)29-27(23)20-13-14-30(18-20)36(31,32)21-9-5-4-6-10-21/h4-14,16-18,29H,15H2,1-3H3

Standard InChI Key:  KTTHUXOEXYKHFJ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA2313487

   2-[1-(benzenesulfonyl)pyrrol-3-yl]-3-[(3,4,5-trimethoxyphenyl)methyl]-1H-indole

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 502.59

Molecular Weight (Monoisotopic): 502.1562

AlogP: 5.49

#Rotatable Bonds: 8

Polar Surface Area: 82.55

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: 5.27

CX LogD: 5.27

Aromatic Rings: 5

Heavy Atoms: 36

QED Weighted: 0.30

Np Likeness Score: -0.34

References

1. La Regina G, Bai R, Rensen WM, Di Cesare E, Coluccia A, Piscitelli F, Famiglini V, Reggio A, Nalli M, Pelliccia S, Da Pozzo E, Costa B, Granata I, Porta A, Maresca B, Soriani A, Iannitto ML, Santoni A, Li J, Miranda Cona M, Chen F, Ni Y, Brancale A, Dondio G, Vultaggio S, Varasi M, Mercurio C, Martini C, Hamel E, Lavia P, Novellino E, Silvestri R..  (2013)  Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.,  56  (1): [PMID:23214452] [10.1021/jm3013097]

2. Zhang S, Yan Z, Li Y, Gong Y, Lyu X, Lou J, Zhang D, Meng X, Zhao Y..  (2022)  Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells.,  65  (8.0): [PMID:35420431] [10.1021/acs.jmedchem.2c00095]

3. Zhang S, Lou J, Li Y, Zhou F, Yan Z, Lyu X, Zhao Y..  (2021)  Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.,  64  (15.0): [PMID:34286973] [10.1021/acs.jmedchem.1c00940]

Source

Source(1):

• Scientific Literature